RETATRUTIDE 120 MG KIT -24 MG / VIAL -5 VIALS
Description:
Dosage:
24 MG / VIALQuantity:
5 VIALSWeight:
0.00000 KGZPHC PHARMA
Zhengzhou Pharmaceutical (ZPHC) is familiar for its stringent quality control standards as well as laboratory-tested preparations, guaranteeing safe and effective medicine and solutions.
Tags :
🧴 RETATRUTIDE 120 MG KIT – 24 MG / VIAL – 5 VIALS – ZPHC PHARMA
🧪 Product Type
Peptide / Multi-Agonist Hormonal Therapy
💉 Active Ingredient
Retatrutide
💉 Dosage Form
Lyophilized powder for reconstitution
💉 Total Kit Strength
120 MG
💉 Vial Strength
24 MG per vial
💉 Package Content
5 vials per kit
📄 Description
RETATRUTIDE by ZPHC Pharma is a next-generation multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed for advanced weight management, metabolic optimization, and type 2 diabetes support. 💉
This formulation is intended for research purposes only, providing insights into how triple agonists influence appetite regulation, insulin sensitivity, and fat oxidation.
🔹 Product Features
- Concentration: 24 MG of Retatrutide per vial
- Total Dose: 120 MG per kit (5 vials × 24 MG)
- Form: Lyophilized powder – requires reconstitution with bacteriostatic water
- Storage: Store refrigerated (2°C–8°C) after reconstitution
- Purity: Pharmaceutical-grade research peptide
✅ Key Research Benefits
🔥 Appetite Suppression: Enhances satiety and reduces caloric intake
💪 Fat Loss & Metabolic Boost: Supports thermogenesis and fat breakdown
💉 Insulin Sensitivity: Improves glucose uptake and beta-cell function
🧪 Triple Receptor Action: Acts on GLP-1, GIP & glucagon receptors for comprehensive metabolic modulation
📈 Suggested Research Use (Investigational Use Only)
Retatrutide is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water before subcutaneous administration.
Dosage, frequency, and duration should follow the parameters of the research protocol.
⚠️ Potential Side Effects (Observed in Research Contexts)
⚠ Nausea or gastrointestinal discomfort
⚠ Reduced appetite
⚠ Mild injection site reactions
⚠ Potential alterations in glucose metabolism
Monitoring is advised during extended study periods.
🚫 Contraindications (Research Advisory)
❌ Not recommended for use in subjects with:
- History of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known allergy to peptide-based therapeutics
🛒 Purchase Information
For research purposes only – Not for human consumption
Supplied as: 120 MG KIT (5 vials × 24 MG)
Manufacturer: ZPHC PHARMA
Ensure authenticity and quality by ordering through certified research suppliers
| Brands | ZPHC PHARMA |